May 2015 Volume 11, Issue 5
Volume 11, Issue 5 | May 2015
May 2015
In this Issue
Preclinical
Vical in- licenses antifungal from Astellas
Preclinical data indicate faster fungicidal activity than marketed drugs and activity against azole-resistant pathogensDye light in the limelight
Okayama University team says light-responsive dye could help combat blindnessEnhancing xenograft use in oncology research
Novel technology from Taconic and Cellaria collaboration could better generate cells from patient-derived tumorsStem cells instead of Viagra?
Liposuction byproduct could cure erectile dysfunction, study suggestsEastern efforts
Covance to begin drug development partnership with China’s Sihuan PharmaceuticalDiscovery
From cancer to heart disease
Bayer and Broad Institute partner to pinpoint genetic roots of cardiovascular disease‘Attracting success’
Evotec, Sanofi launch multifaceted strategic alliance with outsourcing, library sharingA blueprint for new therapies
Blueprint Medicines launches strategic collaboration with Alexion to advance new drug candidates in rare genetic diseaseTargeting two with PTP1B
CSHL-Glaxo collaboration looks to combat diabetes and obesity by regulating enzymatic activity of phosphatase PTP1BResearch & Development
Constructing ‘beautiful, basic science’
Scripps Florida scientists build ribosome assembly process; discover key targets of new anticancer drug candidatesFatty acids to fight cancer
WSU researchers show a mechanism by which omega-3 fatty acids inhibit prostate cancerChemInteract consortium wins funding to assess chemical toxicity
New technology aims to reduce animal testing and improve safety testing of chemicalsCalifornia dreamin’
Amyris, Genome Compiler partner to launch first-of-its-kind DNA design and construction softwareRuthigen and Pulmatrix enter into merger agreement
Upon the closing of the deal, Pulmatrix will become a wholly owned subsidiary of RuthigenGAP and IMI team up to accelerate Alzheimer’s drug development
The organizations will seek to build a global, standing, trial-ready platformImmune dysfunction role in schizophrenia?
UC Davis to establish Conte Center for schizophrenia research to explore novel conceptQ&A
Q&A: 'We all came from the sea…'
We speak to Mark Currie, CSO and president of R&D for Ironwood Pharmaceutical, about treatments for painful intestinal disorders and more.Feature
Stem cells: Taking stock in Stockholm
ISSCR will hold 2015 annual meeting in Sweden as part of its ‘great vision’ of global activityEditor's Focus
21st Century Cures could arrive this century
In what seems so far to be something approaching a truly bipartisan effort and possibly a sincere desire for positive change, Congress tackles draft of potential bill that would advance healthcare and health research, as well as boost NIH fundingBusiness & Government Policy
Getting to the heart of gene therapy
Bristol-Myers Squibb and uniQure to explore gene therapy for cardiovascular diseasesTwo’s company; three’s a crowd?
Mylan makes $29-billion offer for Perrigo, inspiring Teva to make $40-billion offer for MylanBig changes for Coronado
Company changes name to Fortress Biotech and makes some key deals in oncologyPatent Docs: FDA approves Sandoz’s filgrastim biosimilar drug product
Many have pontificated about the benefits of a biosimilar approval pathway in the United States; those predictions have begun the process of being tested with approval of ZarxioOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsThe M&A roundup
Recent merger and acquisition activity in pharma and biotechCommentary
Out of order: Asilomar remembered
Consensus tends to be lacking as to the dividing line between permissible germline genome modification to treat human disease vs. questionable attempts at human enhancement, and that is something we need to sort outCommentary: Intralesional Melanoma Treatments Are Ready for Prime Time
A reprint of a commentary from our Cancer Research News site looking at three candidate drugs currently under investigation as intralesional agents for melanoma treatmentClinical Trials
Keeping pace with Kura
Biopharmaceutical company inks Janssen oncology partnership, completes private placementOne and done
Investigational drug is designed to prevent scarring in dialysis patientsSuperior for skin?
Boehringer Ingelheim compound outperforms Stelara in head-to-head psoriasis studyBigger, faster, better connected
The clinical trials community continues to focus on collaborations and new technology to speed results, cut costsDiagnostics
ConfirmMDx sniffs out prostate cancer
Data supporting expanded use of MDxHealth test presented at ASCO Genitourinary Cancers SymposiumGE Healthcare collaboration targets digital pathology
Effort seeks to give cancer pathology similar computational support as other areas of medicineInnovating with Inivata
Biodesix teams with U.K. genomics company to develop NGS blood-based tests for lung cancerOf a mind for ‘open innovation’
Philips enters collaboration with Janssen on handheld blood test to validate neuropsychiatric disorders
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Reliable fluid biomarkers strategies for clinical neuroscience research
Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
Understanding drug impurities: types, sources, and analytical strategies
Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Discovering cutting-edge nitrosamine analysis in pharmaceuticals
New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
